50
Participants
Start Date
December 31, 2020
Primary Completion Date
March 31, 2025
Study Completion Date
December 31, 2025
Eltrombopag
The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L,the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks,already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
RECRUITING
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER
Tianjin Medical University Second Hospital
OTHER
Tianjin Third Central Hospital
OTHER
Tianjin People's Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
The Second Affiliated Hospital of Kunming Medical University
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER